Galenica and Fresenius form new renal-focused firm
This article was originally published in Scrip
Executive Summary
Fresenius Medical Care and Galenica are to launch a new renal-focused pharmaceutical company called Vifor-Fresenius Medical Care Renal Pharma to develop treatments for iron deficiency anaemia and bone mineral metabolism for pre-dialysis and dialysis patients.
You may also be interested in...
Cara’s Partnership With Vifor Fresenius Provides Validation For Pruritis Drug Korsuva
A Vifor Fresenius joint venture will market Korsuva for CKD-associated pruritis to Fresenius dialysis centers in Europe, and also will do a co-promotion with Cara in the US that may provide a significant head start for the drug.
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.